Literature DB >> 9525626

Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription.

L A Stark1, R T Hay.   

Abstract

The vpr gene of human immunodeficiency virus type 1 (HIV-1) encodes a 96-amino-acid 14-kDa protein (viral protein R [Vpr]), which is produced late in the viral life cycle and is incorporated into the virion. Although Vpr is not required for viral replication in transformed cell lines and primary T lymphocytes, it is essential for productive infection of macrophages and monocytes and appears to be important for pathogenesis in vivo. To establish the role of Vpr in HIV-1 replication and pathogenesis, we have isolated cellular proteins with which Vpr interacts. By using the yeast two-hybrid system, Lys-tRNA synthetase (LysRS) was identified as a Vpr-interacting protein. The interaction between Vpr and LysRS was characterized both in vitro and in vivo, and the domains of Vpr required for the interaction were defined. In the presence of Vpr, LysRS-mediated amino-acylation of tRNA(Lys) is inhibited. Since tRNA(Lys) is the primer for reverse transcription of the HIV-1 genome, this suggests that the interaction between Vpr and LysRS may influence the initiation of HIV-1 reverse transcription.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525626      PMCID: PMC109751     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

Review 1.  HIV accessory proteins as therapeutic targets.

Authors:  R H Miller; N Sarver
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

2.  Coexistence of two antisynthetases in a patient with the antisynthetase syndrome.

Authors:  C Gelpí; E Kanterewicz; J Gratacos; I N Targoff; J L Rodríguez-Sánchez
Journal:  Arthritis Rheum       Date:  1996-04

Review 3.  Recent advances. HIV infection-II.

Authors:  C Beiser
Journal:  BMJ       Date:  1997-02-22

Review 4.  Recent advances. HIV infection--I.

Authors:  J A Cohn
Journal:  BMJ       Date:  1997-02-15

5.  Direct activation of protein phosphatase-2A0 by HIV-1 encoded protein complex NCp7:vpr.

Authors:  H Y Tung; H De Rocquigny; L J Zhao; X Cayla; B P Roques; R Ozon
Journal:  FEBS Lett       Date:  1997-01-20       Impact factor: 4.124

6.  Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1.

Authors:  L Wang; S Mukherjee; O Narayan; L J Zhao
Journal:  Gene       Date:  1996-10-31       Impact factor: 3.688

7.  Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine.

Authors:  T Igarashi; Y Ami; H Yamamoto; R Shibata; T Kuwata; R Mukai; K Shinohara; T Komatsu; A Adachi; M Hayami
Journal:  J Gen Virol       Date:  1997-05       Impact factor: 3.891

8.  Effects of modifying the tRNA(3Lys) anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription.

Authors:  Y Huang; A Shalom; Z Li; J Wang; J Mak; M A Wainberg; L Kleiman
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe.

Authors:  Y Zhao; J Cao; M R O'Gorman; M Yu; R Yogev
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

10.  Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency.

Authors:  D N Levy; Y Refaeli; D B Weiner
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more
  21 in total

1.  Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

Authors:  B E Sawaya; K Khalili; J Gordon; A Srinivasan; M Richardson; J Rappaport; S Amini
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription.

Authors:  D C Hay; G D Kemp; C Dargemont; R T Hay
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 4.  Aminoacyl-tRNA synthetase complexes: molecular multitasking revealed.

Authors:  Corinne D Hausmann; Michael Ibba
Journal:  FEMS Microbiol Rev       Date:  2008-06-03       Impact factor: 16.408

5.  The dose-dependent H2O2 stress response promotes increased survival for Schizosaccharomyces pombe cells expressing HIV-1 Vpr.

Authors:  J Antal; M Pesti
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 6.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

7.  Viral hijacking of mitochondrial lysyl-tRNA synthetase.

Authors:  Monika Kaminska; Vyacheslav Shalak; Mathilde Francin; Marc Mirande
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

Review 8.  Vpr-host interactions during HIV-1 viral life cycle.

Authors:  Richard Y Zhao; Ge Li; Michael I Bukrinsky
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-12       Impact factor: 4.147

9.  The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA.

Authors:  Julien Bischerour; Patrick Tauc; Hervé Leh; Hugues de Rocquigny; Bernard Roques; Jean-François Mouscadet
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

10.  Modulating the activity of the channel-forming segment of Vpr protein from HIV-1.

Authors:  Chin-Pei Chen; Clemens Kremer; Peter Henklein; Ulrich Schubert; Rainer H A Fink; Wolfgang B Fischer
Journal:  Eur Biophys J       Date:  2009-07-24       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.